Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

Xuelian Tan, Timothy Cody Ashby, PhD, Yuqi Zhu, Can Li, MD, Xuxing Shen, MBBS, Qierra Brockman, BA, Dongzheng Gai, MD, Sarah K Johnson, PhD, Donghoon Yong, Carolina D. Schinke, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, John Shaughnessy, Jr., PhD, Dingming Huang, PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140372

Published: 2020

Journal Articles

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Tarun K. Garg, PhD, Cody Ashby, PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2019) 134 (Supplement_1): 4412.

https://doi.org/10.1182/blood-2019-127382

Published: 2019

Journal Articles

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Eileen M Boyle, MD MSc, Faith E. Davies, MD, Shayu Deshpande, Ruslana G. Tytarenko, MS, Cody Ashby, PhD, Yan Wang, Christopher P. Wardell, PhD MSc, BSc, Michael A Bauer, PhD, Sarah K Johnson, PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Louis Williams, MD MBA, Thierry Facon, MD, Charles Dumontet, Bart Barlogie, MD PhD, Gareth Morgan, MDPhDFRCP, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 4333.

https://doi.org/10.1182/blood-2019-126679

Published: 2019

Journal Articles

Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance

Michael A Bauer, PhD, Matthew Henry, M.S., Purvi Patel, Yan Wang, Joshua Epstein, DSc, Faith E. Davies, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Gareth Morgan, MD, Brian A Walker, PhD, Sarah K Johnson, PhD

Blood (2018) 132 (Supplement 1): 4465.

https://doi.org/10.1182/blood-2018-99-119131

Published: 2018

Journal Articles

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Sarah K Johnson, PhD, Stephen Burke, PhD, Matthew Henry, M.S., Amy Greenway, Katie Stone, BS, Brian A Walker, PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4466.

https://doi.org/10.1182/blood-2018-99-119241

Published: 2018

Journal Articles

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2018-99-115244

Published: 2018

Journal Articles

Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria

Eileen M Boyle, MD MSc, Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Yan Wang, Michael A Bauer, PhD, Shayu Deshpande, Sarah K Johnson, PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Christopher Wardell, PhD, Niels Weinhold, PhD, Thierry Facon, Charles Dumontet, Gareth Morgan, MD, Faith E. Davies, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 4456.

https://doi.org/10.1182/blood-2018-99-117193

Published: 2018

Journal Articles

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Blood (2018) 132 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2018-99-119113

Published: 2018

Journal Articles

Deep Immunoprofiling of the Bone Marrow Microenvironmental Changes Underlying the Multistep Progression of Multiple Myeloma

Mary H Young, PhD, Sam A Danziger, Alison Fitch, Frank Schmitz, MD PhD, Jake Gockley, PhD, Mark McConnell, PhD, David Reiss, PhD, Wilbert B. Copeland, PhD, Sarah K Johnson, PhD, Katie Newhall, PhD, Robert Hershberg, MD PhD, Teri Foy, PhD, Alexander Ratushny, PhD, Brian A Walker, PhD, Andrew Dervan, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 243.

https://doi.org/10.1182/blood-2018-99-113042

Published: 2018

Journal Articles

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Brian A Walker, PhD, Cody Ashby, PhD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2018-99-116455

Published: 2018

Journal Articles

Whole-Genome Mate Pair Sequencing Transforms Cytogenetic Analysis of Hematologic Malignancies: Development of a Targeted Panel to Detect Diagnostic/Prognostic Chromosomal Rearrangements and Copy Number Changes in AML

Umut Aypar, PhD, George Vasmatzis, PhD, Sarah K Johnson, PhD, James Smadbeck, PhD, Stephanie A. Smoley, BA, Hutton Kearney, PhD, William Sukov, MD, Rhett P. Ketterling, MD, Katherine Geiersbach, MD, Daniel L. Van Dyke, PhD, Robert Jenkins, MD PhD, Patricia Greipp, DO, Erik Thorland, PhD, Nicole Hoppman, PhD, Linda B Baughn, PhD

Blood (2017) 130 (Supplement 1): 1387.

https://doi.org/10.1182/blood.V130.Suppl_1.1387.1387

Published: 2017

Journal Articles

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

Leo Rasche, MD, Carolina D. Schinke, MD, Daisy Alapat, MD, Grant Gershner, Sarah K Johnson, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, James E McDonald, BS, MD, Rohan Samant, MD, Edgardo Angtuaco, MD, Brian A Walker, PhD, Bart Barlogie, MD PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4510.

https://doi.org/10.1182/blood.V130.Suppl_1.4510.4510

Published: 2017

Journal Articles

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

Whitney Tevebaugh, James Douglas, MS, Brian A Walker, PhD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J. Morgan, MD PhD, Sarah K Johnson, PhD

Blood (2017) 130 (Supplement 1): 4392.

https://doi.org/10.1182/blood.V130.Suppl_1.4392.4392

Published: 2017

Journal Articles

AML-Associated Somatic Mutations Can be Detected in Stem and Progenitor Populations in Patients with Antecedent Multiple Myeloma Years before Onset of Therapy-Related Transformation

Ashwin Sridharan, Carolina D. Schinke, MD, George Georgiev, Mariana Da Silva Ferreira, Kith Pradhan, PhD, Yu Xia, PhD, Maya Panjikaran, MS, Gregory Sims, Chirag Bhagat, Armin Graber, Christoph Heuck, MD, Daisy Alapat, MD, Niels Weinhold, PhD, Sarah K Johnson, PhD, Bart Barlogie, MD PhD, Gareth J. Morgan, MD PhD, Ulrich G. Steidl, MDPhD, Britta Will, PhD, Amit Verma, MD

Blood (2017) 130 (Supplement 1): 2706.

https://doi.org/10.1182/blood.V130.Suppl_1.2706.2706

Published: 2017

Journal Articles

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Christopher P. Wardell, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Shmuel Yaccoby, PhD

Blood (2017) 130 (Supplement 1): 1790.

https://doi.org/10.1182/blood.V130.Suppl_1.1790.1790

Published: 2017

Journal Articles

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Blood (2016) 128 (22): 3278.

https://doi.org/10.1182/blood.V128.22.3278.3278

Published: 2016

Journal Articles

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

Bruno Paiva, PhD, Sarah K. Johnson, PhD, Maria-Victoria Mateos, MD PhD, Daisy V. Alapat, MD, Noemi Puig, MD PhD, Miguel-T Hernandez, Fernando Escalante, Alfonso Garcia de Coca, MD PhD, Joan Bladé, Juan Jose Lahuerta, Quentin Lecrevisse, Jacques J.M. van Dongen, MD PhD, Alberto Orfao, MD PhD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD, Jesus San Miguel, MD PhD

Blood (2016) 128 (22): 373.

https://doi.org/10.1182/blood.V128.22.373.373

Published: 2016

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

Shmuel Yaccoby, PhD, Pingping Qu, PhD, Syed Mehdi, Antje Hoering, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 2065.

https://doi.org/10.1182/blood.V128.22.2065.2065

Published: 2016

Journal Articles

The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States

Brian Koss, Whitney Tevebaugh, Brian A Walker, PhD, Carolina Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MD PhD, Sarah K. Johnson, PhD

Blood (2016) 128 (22): 4438.

https://doi.org/10.1182/blood.V128.22.4438.4438

Published: 2016

NARROW

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Deep Immunoprofiling of the Bone Marrow Microenvironmental Changes Underlying the Multistep Progression of Multiple Myeloma

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Whole-Genome Mate Pair Sequencing Transforms Cytogenetic Analysis of Hematologic Malignancies: Development of a Targeted Panel to Detect Diagnostic/Prognostic Chromosomal Rearrangements and Copy Number Changes in AML

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

AML-Associated Somatic Mutations Can be Detected in Stem and Progenitor Populations in Patients with Antecedent Multiple Myeloma Years before Onset of Therapy-Related Transformation

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma

The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only